Outlook Therapeutics, Inc.
OTLK Nasdaq
SEC CIK 1649989
Follow Outlook Therapeutics
Weekly email: filings, results
Net income
−$20.3M
−0.8% vs same quarter last year
EPS, diluted
−$0.15
+72.7% vs same quarter last year
Operating cash flow
−$21M
−76.5% vs same quarter last year
Operating income
−$10.8M
+31.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.4M | −$62.4M |
| FY24 | - | −$75.4M |
| FY23 | - | −$59M |
| FY22 | - | −$66.1M |
| FY21 | - | −$53.2M |
| FY20 | - | −$35.2M |
| FY19 | $8.1M | −$34.5M |
| FY18 | $3.1M | −$30.1M |
| FY17 | $3.8M | −$38.8M |
| FY16 | $3M | −$53.3M |
| FY15 | $5.2M | −$47.4M |
| FY14 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −4744.3% | −4416.2% |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | −445.6% | −423.8% |
| FY18 | −960.1% | −974.6% |
| FY17 | −941.4% | −1019.3% |
| FY16 | −1723.3% | −1788.9% |
| FY15 | −892.1% | −908.1% |
| FY14 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | −$32.7M |
| FY18 | −$35.8M |
| FY17 | −$15.8M |
| FY16 | −$46.6M |
| FY15 | −$36.3M |
| FY14 | - |
- Outlook Therapeutics
- Healthcare median
Show the numbers
| Year | Outlook Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −4416.2% | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | −423.8% | −46.3% |
| FY18 | −974.6% | −49.6% |
| FY17 | −1019.3% | −45.9% |
| FY16 | −1788.9% | −36% |
| FY15 | −908.1% | −38.4% |
| FY14 | - | −35.5% |